Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antitumor Activity of NVP-BKM120—A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma Cells

8 Nov 2011

Abstract excerpt

PURPOSE: The aim of this study was to show preclinical efficacy and clinical development potential of NVP-BKM120, a selective pan class I phosphatidylinositol-3 kinase (PI3K) inhibitor in human glioblastoma (GBM) cells in vitro and in vivo. EXPERIMENTAL DESIGN: The effect of NVP-BKM120 on cellular growth was assessed by CellTiter-Blue assay. Flow cytometric analyses were carried out to measure the cell-cycle,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related Molecular Pathways
Share to Microtubule and mitosis dynamics
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 22065080
DOI: 10.1158/1078-0432.ccr-11-1558

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antitumor Activity of NVP-BKM120—A Selective Pan Class I PI3 Kinase Inhibitor Showed Differential Forms of Cell Death Based on p53 Status of Glioma CellsPMID 22065080Read ↗

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.Semantic proximity Read ↗

PI3Kinase signaling in glioblastoma.Semantic proximity Read ↗

Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF-05212384.Semantic proximity Read ↗

A Potential Role for the Inhibition of PI3K Signaling in Glioblastoma TherapySemantic proximity Read ↗

Targeted therapy for malignant glioma patients: lessons learned and the road ahead.Semantic proximity Read ↗

Will kinase inhibitors make it as glioblastoma drugs?Semantic proximity Read ↗

PI3K Signaling in Glioma—Animal Models and Therapeutic ChallengesSemantic proximity Read ↗

Transcriptional CDK inhibitors, CYC065 and THZ1 promote Bim-dependent apoptosis in primary and recurrent GBM through cell cycle arrest and Mcl-1 downregulationSemantic proximity Read ↗

BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant gliomaSemantic proximity Read ↗

A high-throughput drug combination screen identifies an anti-glioma synergism between TH588 and PI3K inhibitorsSemantic proximity Read ↗

Lack of Constitutively Active DNA Repair Sensitizes Glioblastomas to Akt Inhibition and Induces Synthetic Lethality with Radiation Treatment in a p53-Dependent MannerSemantic proximity Read ↗

Monotherapy efficacy of BBB-permeable small molecule activators of PP2A in glioblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.